<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02335983</url>
  </required_header>
  <id_info>
    <org_study_id>CFZ013</org_study_id>
    <nct_id>NCT02335983</nct_id>
  </id_info>
  <brief_title>Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma</brief_title>
  <official_title>Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety, tolerability and activity of a once-weekly
      regimen of carfilzomib in combination with lenalidomide and dexamethasone for the treatment
      of multiple myeloma.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 2015</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>54 months</time_frame>
    <description>Safety and tolerability of carfilzomib administered once weekly in combination with lenalidomide and dexamethasone, as defined by the type, incidence, severity, and outcome of Adverse Events (AEs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Laboratory Values</measure>
    <time_frame>54 months</time_frame>
    <description>Changes from baseline in key laboratory analyses</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total Plasma Exposure - Area Under the Curve (AUC)</measure>
    <time_frame>58 months</time_frame>
    <description>Total Plasma Exposure - Area Under the Curve (AUC) will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for AUC will be tabulated and summarized (i.e., mean, standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>58 months</time_frame>
    <description>Maximum plasma concentration (Cmax) will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for Cmax will be tabulated and summarized (i.e., mean, standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Plasma Concentration (Tmax)</measure>
    <time_frame>58 months</time_frame>
    <description>Time to Peak Concentration (Tmax) will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for Tmax will be tabulated and summarized (i.e., mean, standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Plasma Clearance</measure>
    <time_frame>58 months</time_frame>
    <description>Total Plasma Clearance will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for Total Plasma Clearance will be tabulated and summarized (i.e., mean, standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Terminal Half-life</measure>
    <time_frame>58 months</time_frame>
    <description>Plasma Terminal Half-life (as appropriate for data collected) will be derived from levels of carfilzomib assayed in Pharmacokinetic (PK) samples. Estimates for Plasma Terminal Half-life will be tabulated and summarized (i.e., mean, standard deviation).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>58 months</time_frame>
    <description>Overall Response Rate (ORR) is defined as the proportion of subjects who achieve a best overall response of stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response Rate (CRR)</measure>
    <time_frame>58 months</time_frame>
    <description>Complete Response Rate (CRR) is defined as the proportion of subjects who achieve a best overall response of either stringent complete response (sCR), complete response (CR) in accordance with International Myeloma Working Group-Uniform Response Criteria (IMWG-URC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>58 months</time_frame>
    <description>Progression-free survival (PFS) is defined as the time from the first day of study treatment to the earlier of disease progression or death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>58 months</time_frame>
    <description>Duration of Response (DOR) is defined as the time from the first evidence of confirmed partial response (PR) or better to disease progression or death due to any cause among subjects who respond.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">107</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose level combination regimen of carfilzomib 56 mg/m2, lenalidomide 25 mg, and dexamethasone 40 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a dose level combination regimen of carfilzomib 70 mg/m2, lenalidomide 25 mg, and dexamethasone 40 mg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: Part 2 - Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed multiple myeloma subjects will receive the regimen selected by the Cohort Safety Review Committee (CSRC) in the Dose-evaluation component.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: Part 2 - Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Relapsed multiple myeloma subjects will receive the regimen selected by the Cohort Safety Review Committee (CSRC) in the Dose-evaluation component.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly Diagnosed multiple myeloma subjects will receive a 2-step-up regimen of carfilzomib at 56 mg/m2 in Cycle 1 and then at 70 mg/m2 beginning with Cycle 2, lenalidomide 25 mg and dexamethasone 40 mg. (note: all subjects receive 20 mg/m2 carfilzomib on Cycle 1 Day 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose-expansion: Part 2 - Arm 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Newly diagnosed multiple myeloma subjects will receive a combination regimen of carfilzomib 56 mg/m2, lenalidomide 25 mg and dexamethasone 40 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carfilzomib</intervention_name>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 1</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 2</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 1</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 2</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 4</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 3</arm_group_label>
    <other_name>PR-171</other_name>
    <other_name>PR171</other_name>
    <other_name>Kyprolis® (carfilzomib) for Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 1</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 2</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 1</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 2</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 4</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 3</arm_group_label>
    <other_name>Revlimid®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 1</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 2</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 1</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 2</arm_group_label>
    <arm_group_label>Dose-evaluation: Part 1 - Cohort 4</arm_group_label>
    <arm_group_label>Dose-expansion: Part 2 - Arm 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Newly diagnosed or relapsed multiple myeloma

          2. Measureable disease by Serum M protein, or Urine M protein, or serum free light chain
             (SFLC) and an abnormal serum kappa lambda ratio (for subjects without detectable serum
             or urine M-protein), or Serum quantitative immunoglobulin A (qlgA) (for immunoglobulin
             (Ig) A subjects whose disease can only be reliable measured by qlgA).

          3. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 to 2

          4. Left ventricular ejection fraction (LVEF) ≥ 40%

        Key Exclusion Criteria:

          1. Waldenström macroglobulinemia

          2. For newly diagnosed multiple myeloma: multiple myeloma of IgM subtype

          3. For relapsed disease:

               1. If treated with a lenalidomide and dexamethasone combination, progression during
                  the first 3 months after initiating treatment.

               2. Any progression during treatment if the lenalidomide and dexamethasone regimen
                  was the most recent line of therapy.

               3. Any prior treatment with carfilzomib

          4. POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and
             skin changes)

          5. Plasma cell leukemia (&gt; 2.0 × 10^9/L circulating plasma cells by standard
             differential)

          6. Myelodysplastic syndrome

          7. Amyloidosis

          8. Prior treatment with carfilzomib or oprozomib
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Saint Joseph Medical Center</name>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Compassionate Care Research Group, Inc.</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Los Angeles Hematology / Oncology Medical Group</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center, Pediatric Hematology Oncology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Partners Cancer Care</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>John Theurer Cancer Center at Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Coleman, MD</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stony Brook University Medical Center</name>
      <address>
        <city>Stony Brook</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham Veterans Affairs Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bend Memorial Clinic</name>
      <address>
        <city>Bend</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina, Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Health System</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital Cancer Center</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Avera Cancer Institute</name>
      <address>
        <city>Sioux Falls</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The West Clinic, PC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC / The Sarah Cannon Research lnstitute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aurora Health Care, Aurora Cancer Care</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2014</study_first_submitted>
  <study_first_submitted_qc>January 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2015</study_first_posted>
  <last_update_submitted>December 15, 2017</last_update_submitted>
  <last_update_submitted_qc>December 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

